Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Secukinumab

Brand: Cosentyx ®
NICE TA: 407
Indication: Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (NICE TA407)
Disease category: Musculoskeletal system
Commissioning responsibility: CCG
PbR excluded: Yes

Background

Secukinumab is recommended, within its marketing authorisation, as an option for treating active ankylosing spondylitis in adults whose disease has responded inadequately to conventional therapy (non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors). The drug is recommended only if the company provides it with the discount agreed in the patient access scheme.
Assess the response to secukinumab after 16 weeks of treatment and only continue if there is clear evidence of response, defined as:
 a reduction in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score to 50% of the more units and
 a reduction in the spinal pain visual analogue scale (VAS) by 2 cm or more.
When using BASDAI and spinal pain VAS scores, healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect the responses to the questionnaires, and make any adjustments they consider appropriate.

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red